Daniel M. Portnoy

Mr. Daniel M. Portnoy


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MPMatthieu Paiola
Matthieu Paiola
DPDaniel M. Portnoy
Daniel M. Portnoy
LHLuke Yi Hao
Luke Yi Hao
SBShoiab Bukhari
Shoiab Bukhari
RWRobert Winchester
Robert Winchester
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
Objective: Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, but they can also lead to immune-related adverse events (irAEs), including inflammatory arthritis. Understanding the risk factors and underlying mechanisms of irAE pathogenesis is crucial for optimal patient management. Increasing evidence suggests that ICI-mediated activation of tissue-resident memory T cells (T RM ) significantly eliminates cancer cells and is associated with irAE-related colitis and dermatitis. However, it remains unknown why the development of these irAEs is restricted to a subset of patients. We hypothesized that osteoarthritis (OA) associated tissue damage and chronic inflammation lead to the recruitment and differentiation of joint T RM cells, predisposing individuals to ICI-induced arthritis. Methods: Using a comprehensive approach, we compared the prevalence of OA in patients with irAE-arthritis to those with irAE non-arthritis and those without irAEs. Additionally, we used advanced immunophenotyping techniques to characterize T-cell populations in the blood and synovial fluid of patients with OA and irAE-arthritis. Results: Our findings revealed a significantly higher prevalence of OA in patients who developed irAE-arthritis than controls. Furthermore, the multivariable analysis identified OA, body mass index, and smoking as independent risk factors for the development of irAE-arthritis. T RM cells expressing programmed cell death protein-1 (PD-1) were the predominant synovial T cells in OA joints. These cells were directly targeted by ICIs, resulting in an inflammatory immune response and the transition from OA to irAE-arthritis. Conclusion: This study, the first of its kind, identifies OA as a significant risk factor for irAEarthritis. It reveals a potential mechanism by which ICIs activate PD-1-positive T RM cells in OA joints, resulting in tissue inflammation and irAE-arthritis. This research could significantly enhance the management and treatment of patients with cancer receiving ICIs.

14 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DPDaniel M. Portnoy
Daniel M. Portnoy
MPMatthieu Paiola
Matthieu Paiola
CTCarly Tymm
Carly Tymm
RWRobert Winchester
Robert Winchester
AMAdam Mor
Adam Mor
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
Osteoarthritis (OA) is the most prevalent form of arthritis and is a major global health burden. OA is a heterogeneous condition with multiple contributing mechanisms that characterize different subtypes and stages of the disease. In this review, we examine the insights gained into the immunological characteristics of OA that have emerged from the increasingly widespread use of checkpoint inhibitors in the immunotherapy of malignancies. We discuss how the conventional view of OA as a degenerative disease is changing in view of the evidence suggesting that OA has an inflammatory component along with the presence in joint tissue of peripherally tolerized autoreactive resident memory T cells, which upon release of their inhibition by immunotherapy mediate immune-related adverse event arthritis (irAE-arthritis). We review clinical trials evaluating the efficacy of immunosuppressive therapies in modifying the course of OA, thereby providing an additional perspective on the presence and nature of the inflammation in OA. In summary, we argue that a shift from the traditional understanding of OA as a mechanical disease to one that incorporates the role of synovial immune cells and mechanisms of self-tolerance is necessary to guide future therapies, including the use of immune checkpoints for patients with OA.

15 July 2026 in The Journal of Rheumatology
Verified
Journal Article
Closed access
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
MPMatthieu Paiola
Matthieu Paiola
DPDaniel M. Portnoy
Daniel M. Portnoy
RWRobert Winchester
Robert Winchester
AMAdam Mor
Adam Mor